Gordon Crofoot

1 week ago | ajmc.com | Julia Bonavitacola |Gordon Crofoot

Cost could make lenacapavir (Sunlenca; Gilead) inaccessible for people who would like to use it as a means of pre-exposure prophylaxis (PrEP) in the prevention of HIV, explained Gordon Crofoot, MD, PA, president and principal investigator at The Crofoot Research Center. Although the treatment is nearly 100% effective, the price point could make rollout slow in vulnerable populations. This transcript has been lightly edited for clarity; captions are auto-generated.

1 week ago | ajmc.com | Julia Bonavitacola |Gordon Crofoot

Gordon Crofoot, MD, PA, president and principal investigator at The Crofoot Research Center, emphasized how much lenacapavir could change the landscape of HIV care with its approval by the FDA for use as pre-exposure prophylaxis (PrEP). This approval could help to eradicate HIV if it is made available for those at the highest risk of contracting and transmitting the virus, he said. This transcript has been lightly edited for clarity; captions were auto-generated.

3 weeks ago | ajmc.com | Julia Bonavitacola |Gordon Crofoot

Gordon Crofoot, MD, PA, president and principal investigator at The Crofoot Research Center, spoke about the pros and cons of lenacapavir when it was studied in the PURPOSE trials, emphasizing what doctors and patients need to know should it be approved by the FDA for use as pre-exposure prophylaxis (PrEP) for HIV. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptWhat were some pros and cons of lenacapavir in the PURPOSE trials?

3 weeks ago | ajmc.com | Julia Bonavitacola |Gordon Crofoot

Gordon Crofoot, MD, PA, president and principal investigator at The Crofoot Research Center, spoke about how lenacapavir can be used as both a means of prevention and treatment of HIV as the approval decision on lenacapavir approaches later in June. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptHow does lenacapavir work to treat and prevent HIV? It works both ways. Lenacapavir is in a brand new class of drugs called a capsid inhibitor.